Find Information About:

Drugs & Supplements

Get information and reviews on prescription drugs, over-the-counter medications, vitamins, and supplements. Search by name or medical condition.

Pill Identifier

Pill Identifier

Having trouble identifying your pills?

Enter the shape, color, or imprint of your prescription or OTC drug. Our pill identification tool will display pictures that you can compare to your pill.

Get Started
My Medicine

My Medicine

Save your medicine, check interactions, sign up for FDA alerts, create family profiles and more.

Get Started

WebMD Health Experts and Community

Talk to health experts and other people like you in WebMD's Communities. It's a safe forum where you can create or participate in support groups and discussions about health topics that interest you.

  • Second Opinion

    Second Opinion

    Read expert perspectives on popular health topics.

  • Community


    Connect with people like you, and get expert guidance on living a healthy life.

Got a health question? Get answers provided by leading organizations, doctors, and experts.

Get Answers

Sign up to receive WebMD's award-winning content delivered to your inbox.

Sign Up

Melanoma/Skin Cancer Health Center

Font Size

Melanoma Patient Tumor Free in T-Cell Clone Study

Immune Therapy for Late-Stage Melanoma: No More Cancer in 1 of 11 Patients

Melanoma Treatment 'Renaissance'

That's not the end of the story. Researchers are also combining their adoptive immunotherapy regimens with other types of immune therapies.

One of these treatments, Yervoy, was recently approved by the FDA. Yervoy is a man-made antibody that attacks melanoma tumors.

By combining adoptive immunotherapy with Yervoy, the researchers hope to deliver a potent one-two punch to late-stage melanoma, no matter how extensively the cancer has spread through the body.

For example, only about 16% of patients respond to Yervoy treatment alone. But when Butler's team gave Yervoy to patients who had already received adoptive immunotherapy, they had more success: Three of five patients had partial tumor remission and two others had stable disease.

"Among investigators, we agree almost certainly that immune therapy is going to work when we combine different agents," says Butler, soon to become an assistant professor at the University of Toronto.

Yee says that although adoptive immunotherapy studies began with melanoma patients, the treatment should work for other types of cancer.

"We are starting to look at ovarian cancer and sarcoma," Yee says.

While adoptive immunotherapy remains on the drawing board, Yee and Butler encourage patients to enroll in clinical trials.

"There are more options for melanoma now than ever before," Yee says. "But if patients volunteer for reasonable clinical trials, we think patients can move science forward faster. We are grateful to the patients who are brave enough to explore this new frontier. This is almost like a renaissance period for immunotherapy."

Yee's study appears in the March 5 early online edition of the Proceedings of the National Academy of Science. Butler's study appeared in the April 27, 2011, issue of Science Translational Medicine.

1 | 2

Today on WebMD

Malignant melanoma
About 40-50 percent of those who live to be 65 may get it. Here’s how to spot early.
Woman checking out tan lines
There’s a dark side to that strive for beauty. See them here.
sauteed cherry tomatoes
Fight cancer one plate at a time.
Lung cancer xray
See it in pictures, plus read the facts.
12 Ways to Protect Your Skin from Melanoma
precancerous lesions slideshow
Do You Know Your Melanoma ABCs
15 Cancer Symptoms Men Ignore
screening tests for men
Vitamin D
Is That Mole Skin Cancer
Brilliant sun rays